A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 5, 2014

Genetically Modifying Cells to Resist HIV Shows Promise

CROI 2014A technique for genetically modifying the immune cells of people with HIV to resist the virus has shown promise in an early safety trial, raising the hope that such treatment may one day offer an alternative to daily antiretroviral (ARV) therapy, The New York Times reports. Publishing their findings in The New England Journal of Medicine, investigators used Sangamo BioSciences’ zinc-finger nucleases (ZFNs) technology to manipulate CD4 cell genes.

Researchers drew CD4 cells from 12 HIV-positive participants on stable ARVs and used the ZFN tool to edit the cells’ genetic code for the CCR5 receptor so as to resist the virus. Most variants of HIV must use the CCR5 receptor in order to enter the cell. The investigators then prompted the cells to multiply and eventually infused each participant with 10 billion of their own CD4 cells, about a fifth of which had a mutated CCR5 gene.

After four weeks, six of the participants stopped taking their ARVs in a planned treatment interruption that was intended to last 12 weeks. All of their viral loads were undetectable at the beginning of the treatment interruption and eventually became detectable before they returned to HIV therapy. Two began ARVs again eight weeks into the interruption because of rapidly rising viral loads.

On average, the peak viral loads of the four participants who completed the full 12-week interruption were more than 90 percent lower than their pre-ARV peak levels. In one of the participants, who the investigators discovered already had the beneficial CCR5 mutation in half of his or her genes, the viral load peaked at 6,247 at week six, after which it declined to an undetectable level.

Investigators concluded that the treatment was generally safe and that the modified CD4s appeared to be resistant to HIV.

To read the National Institutes of Health press release, click here.

To read the Times story, click here.

Search: ZFN, zinc-finger nucleases, Sangamo BioSciences, New England Journal of Medicine, CCR5 mutation.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    Hillcrester
    Ramona
    California


    koffeeboss
    Tucson
    Arizona


    max38man
    Chicago
    Illinois


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.